An Intra-patient Placebo-controlled, Phase I Clinical Study, to Evaluate the Safety and Tolerability of Intradermal IMM-101 (Heat-killed Mycobacterium Obuense) in Adult Melanoma Cancer Patients

Trial Profile

An Intra-patient Placebo-controlled, Phase I Clinical Study, to Evaluate the Safety and Tolerability of Intradermal IMM-101 (Heat-killed Mycobacterium Obuense) in Adult Melanoma Cancer Patients

Completed
Phase of Trial: Phase I

Latest Information Update: 08 Nov 2015

At a glance

  • Drugs IMM 101 (Primary)
  • Indications Malignant melanoma
  • Focus Adverse reactions
  • Sponsors Immodulon Therapeutics
  • Most Recent Events

    • 05 Dec 2012 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 30 Mar 2012 Status changed from completed to recruiting, based on the ClinicalTrials.gov record NCT01559818.
    • 10 Mar 2011 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top